US · Healthcare · Biotechnology
EPS came in at -0.62 against a street estimate of -0.63 — a beat of 1.6%.
Analysts rate Acurx Pharmaceuticals LLC a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $17.00.
| Fund | Stake |
|---|---|
| Jane Street Group LLC | 1.27% |
| Vanguard Capital Management, LLC | 0.72% |
| Geode Capital Management, LLC | 0.58% |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 0.47% |
| Vanguard Fiduciary Trust Co | 0.38% |
| Prospect Financial Services Llc | 0.32% |
| Morgan Stanley - Brokerage Accounts | 0.15% |
| UBS Group AG | 0.15% |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Acurx Pharmaceuticals LLC — free to start.
Google PlayApp StoreData updated 2026-08-05.